Risk-based treatment for synovial sarcoma in patients under 30 years of age: Children’s Oncology Group study ARST0332.
Rajkumar Venkatramani(Baylor College of Medicine), Sheri L. Spunt(BVI (United States)), Lynn Million(VA Palo Alto Health Care System), Simon C. Kao(University of Iowa), Beth McCarville(St. Jude Children's Research Hospital), Rose Anne Speights(St. Jude Children's Research Hospital), David M. Parham(Children's Hospital of Los Angeles), R. Lor Randall(University of California Davis Medical Center), Andrea Hayes‐Jordan(The University of Texas MD Anderson Cancer Center), Suzanne L. Wolden(Memorial Sloan Kettering Cancer Center), Jennifer O. Black(Children's Hospital Colorado), Douglas S. Hawkins(Seattle Children's Hospital), Stephanie Terezakis(University of Minnesota), Fran Laurie(University of Massachusetts Chan Medical School), Cheryl M. Coffin(University of Utah), Stephen X. Skapek(Duke University)
Cited by 2
Related Papers
Comprehensive Genomic Analysis of Rhabdomyosarcoma Reveals a Landscape of Alterations Affecting a Common Genetic Axis in Fusion-Positive and Fusion-Negative Tumors
|Cancer Discovery|2014|789
Soft Tissue Sarcoma, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2018|733
Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohort
|European Journal of Cancer|2019|724
Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial
|The Lancet Oncology|2016|537
Intensity-modulated radiation therapy (IMRT) for nasopharynx cancer: Update of the Memorial Sloan-Kettering experience
|International Journal of Radiation Oncology*Biology*Physics|2005|421